GSK & Innoviva Announce Approval Of Relvar Ellipta In Japan For COPD
LONDON (dpa-AFX) - GlaxoSmithKline plc (GSK, GSK.L) and Innoviva, Inc. (INVA) announced the Japanese Ministry of Health, Labour and Welfare has approved Relvar Ellipta for the relief of various symptoms with chronic obstructive pulmonary disease.
Relvar Ellipta has been approved in Japan for the treatment of asthma since 2013.
The respiratory partnership between Innoviva and Glaxo include, RELVAR/BREO ELLIPTA and ANORO ELLIPTA, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR/BREO ELLIPTA, ANORO ELLIPTA and, if approved and commercialized, VI monotherapy, as well.
Copyright RTT News/dpa-AFX
|17,951 €||17,859 €||0,092 €||+0,52%||02.12./18:59|
|GB0009252882||940561||20,55 €||17,10 €|
|Nasdaq OTC Other||18,55 $||+0,22%||16:29|